Noradrenergic-selective reuptake inhibitors

Schuldiner, S (1998) Vesicular neurotransmitter transporters. In Neurotransmitter Transporters Structure, Function, and Regulation (Ed. Reith, MEA), Humana Press, Totowa, NJ, pp. 215-240. Stanford, SC (1995) Central noradrenergic neurones and stress. Pharmac. Ther. 68 297-342. Stanford, SC (1999) SSRI-induced changes in catecholaminergic transmission. In Selective Serotonin Reuptake Inhibitors (SSRIs) Past, Present and Future (Ed. Stanford, SC), RG Landes Co., Austin, TX, pp. 147-170. 

MAOI, monoamine oxidase inhibitor NaSSA, noradrenergic and specific serotonergic antidepressant NDRI, norepinephrine and dopamine reuptake inhibitor SARI, serotonin antagonist and reuptake inhibitor SNRI, serotonin and norepinephrine reuptake inhibitor SSRI, selective serotonin reuptake inhibitor TCA, tricyclic antidepressant. 

The low side effect profile, ease of use, and powerful clinical effect of the selective serotonin reuptake inhibitors (SSRIs) revolutionized the treatment of depression and anxiety in the 1990s. The success of the SSRIs shifted the focus from noradrenergic to serotonergic mechanisms in these common disorders. 

Classical Antidepressants, Serotonin Selective Reuptake Inhibitors, and Noradrenergic Reuptake Inhibitors... 

In this chapter, we will review pharmacological concepts underlying the use of several classes of antidepressant drugs, including the classical monoamine oxidase (MAO) inhibitors, the classical tricyclic antidepressants, the popular serotonin selective reuptake inhibitors (SSRIs), and the new selective noradrenergic reuptake... 

---